A review of anti-inflammatory agents for symptoms of schizophrenia

Journal of Psychopharmacology

Volumn 27, Issue 4, 2013, Pages 337-342

  Keller, William R ^a   Kum, Lionel M ^a   Wehring, Heidi J ^a   Koola, Maju Mathew ^a   Buchanan, Robert W ^a   Kelly, Deanna L ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

aspirin; cytokines; Inflammation; minocycline; omega 3 fatty acids; schizophrenia

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ACETYLSALICYLIC ACID; AMISULPRIDE; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DEXTROMETHORPHAN; DOCOSAHEXAENOIC ACID; DOPAMINE; GAMMA INTERFERON; ICOSAPENTAENOIC ACID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MINOCYCLINE; NEUROSTEROID; NITRIC OXIDE SYNTHASE; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; PREGNENOLONE; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; RISPERIDONE; SALSALATE; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ATTENTION; CLINICAL GLOBAL IMPRESSION SCALE; DRUG ABSORPTION; DRUG PENETRATION; DRUG RESEARCH; ENZYME INHIBITION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INFLAMMATION; NEUROPROTECTION; NONHUMAN; NUTRITIONAL DEFICIENCY; PATHOGENESIS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERBAL MEMORY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; FATTY ACIDS, OMEGA-3; HUMANS; MINOCYCLINE; NEUROTRANSMITTER AGENTS; SCHIZOPHRENIA;

EID: 84875701075     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112467089     Document Type: Review

References (51)

1. Aid S, Bosetti F. Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications. Biochimie. 2011 ; 93: 46-51
2. Akhondzadeh S, Tabatabaee M, Amini H, et al. Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophr Res. 2007 ; 90: 179-185
3. Amminger GP, Schafer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010 ; 67: 146-154
4. Benros ME, Nielsen PRi, Nordentoft M, et al. Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register study. Am J Psychiatry. 2011 ; 168: 1303-1310
5. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: A review of epidemiologic and translational studies. Am J Psychiatry. 2010 ; 167: 261-280
6. Brown AS, Hooton J, Schaefer CA, et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry. 2004 ; 161: 889-895
7. Charalampopoulos I, Tsatsanis C, Dermitzaki E, et al. Dehydroepiandrosterone and allopregnanolone protect sympathoadrenal medulla cells against apoptosis via antiapoptotic Bcl-2 proteins. Proc Natl Acad Sci U S A. 2004 ; 101: 8209-8214
8. Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefits negative symptoms in early schizophrenia; a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012 ; 26: 1185-1193
9. Emsley R, Myburgh C, Oosthuizen P, et al. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry. 2002 ; 159: 1596-1598
10. Fan X, Goff DC, Henderson DC. Inflammation and schizophrenia. Expert Rev Neurother. 2007 ; 7: 789-796
11. Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry. 2001 ; 158: 2071-2074
12. Giuliani F, Hader W, Yong VW. Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction. J Leukoc Biol. 2005 ; 78: 135-143
13. Goldfine AB, Silver R, Aldhahi W, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008 ; 1: 36-43
14. Hanson DR, Gottesman II. Theories of schizophrenia: A genetic-inflammatory-vascular synthesis. BMC Med Genet. 2005 ; 6: 7
15. He J, Evans CO, Hoffman SW, et al. Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. Exp Neurol. 2004 ; 189: 404-412
16. Howes OD, Fusar-Poli P, Bloomfield M, et al. From the prodrome to chronic schizophrenia: The neurobiology underlying psychotic symptoms and cognitive impairments. Curr Pharm Des. 2012 ; 18: 459-465
17. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry. 2004 ; 9: 984-997
18. Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev. 2006 ;:
19. Kelly DL, Vyas G, Richardson CM, et al. Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr Res. 2011 ; 133: 257-258
20. Klein NC, Cunha BA. Tetracyclines. Med Clin North Am. 1995 ; 79: 789-801
21. Koenig HL, Schumacher M, Ferzaz B, et al. Progesterone synthesis and myelin formation by Schwann cells. Science. 1995 ; 268: 1500-1503
22. Laan W, Grobbee DE, Selten JP, et al. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010 ; 71: 520-527
23. Lai AY, Todd KG. Hypoxia-activated microglial mediators of neuronal survival are differentially regulated by tetracyclines. Glia. 2006 ; 53: 809-816
24. Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010 ; 71: 138-149
25. Li G, Cui G, Tzeng NS, et al. Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage. FASEB J. 2005 ; 19: 489-496
26. MacDougall C Goodman & Gilman's The Pharmacological Basis of Therapeutics. 2011 ) Protein synthesis inhibitors and miscellaneous antibacterial agents. In: ChabnerBABruntonLLKnollmanBC (eds) Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill. Chabner BA Brunton LL Knollman BC, ed. New York: McGraw-Hill ; 2011 :
27. Marx CE, Bradford DW, Hamer RM, et al. Pregnenolone as a novel therapeutic candidate in schizophrenia: Emerging preclinical and clinical evidence. Neuroscience. 2011 ; 191: 78-90
28. Marx CE, Keefe RS, Buchanan RW, et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology. 2009 ; 34: 1885-1903
29. Marx CE, Shampine LJ, Duncan GE, et al. Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: Candidate mechanism for superior efficacy?. Pharmacol Biochem Behav. 2006 ; 84: 598-608
30. Miller BJ, Buckley P, Seabolt W, et al. Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. Biol Psychiatry. 2011 ; 70: 663-671
31. Miyaoka T. Clinical potential of minocycline for schizophrenia. CNS Neurol Disord Drug Targets. 2008 ; 7: 376-381
32. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 2009 ; 63: 257-265
33. Muller N, Krause D, Dehning S, et al. Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res. 2010 ; 121: 118-124
34. Muller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002 ; 159: 1029-1034
35. Muller N, Ulmschneider M, Scheppach C, et al. COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci. 2004 ; 254: 14-22
36. Nikodemova M, Watters JJ, Jackson SJ, et al. Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII. J Biol Chem. 2007 ; 282: 15208-15216
37. Peet M, Stokes C.. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs. 2005 ; 65: 1051-1059
38. Peet M, Brind J, Ramchand CN, et al. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res. 2001 ; 49: 243-251
39. Potvin S, Stip E, Sepehry AA, et al. Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review. Biol Psychiatry. 2008 ; 63: 801-808
40. Raffa M, Atig F, Mhalla A, et al. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry. 2011 ; 11: 124
41. Rapaport MH, Delrahim KK, Bresee CJ, et al. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry. 2005 ; 57: 1594-1596
42. Ritsner MS, Gibel A, Shleifer T, et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: An 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry. 2010 ; 71: 1351-1362
43. Schwarz MJ, Muller N, Riedel M, et al. The Th2-hypothesis of schizophrenia: A strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses. 2001 ; 56: 483-486
44. Serhan CN. Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators. Prostaglandins Leukot Essent Fatty Acids. 2008 ; 79: 157-163
45. Shi J, Levinson DF, Duan J, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature. 2009 ; 460: 753-757
46. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007 ; 132: 2169-2180
47. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002 ; 21: 495-505
48. Stefansson H, Rujescu D, Cichon S, et al. Large recurrent microdeletions associated with schizophrenia. Nature. 2008 ; 455: 232-236
49. Wu FS, Gibbs TT, Farb DH. Pregnenolone sulfate: A positive allosteric modulator at the N-methyl-D-aspartate receptor. Mol Pharmacol. 1991 ; 40: 333-336
50. Yao JK, Magan S, Sonel AF, et al. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 2004 ; 71: 171-176
51. Yrjanheikki J, Keinanen R, Pellikka M, et al. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A. 1998 ; 95: 15769-15774